Marschall S Runge

Title: Marschall S Runge: Innovator in Hybrid Factor VIII Research

Introduction

Marschall S Runge is a prominent inventor based in Atlanta, GA (US), known for his significant contributions to the field of biotechnology and medicine. He holds a total of 8 patents, showcasing his innovative approach to solving complex medical challenges.

Latest Patents

One of his latest patents involves the development of hybrid human/animal factor VIII. This hybrid procoagulant factor VIII is produced through the isolation and recombination of human and nonhuman mammalian factor VIII subunits or domains, or by genetic engineering of the respective genes. The process includes mixing animal heavy chain subunits with human light chain subunits, or vice versa, to create hybrid molecules that can be administered to patients with factor VIII deficiency. Additionally, Runge has worked on hybrid immunoglobulin-thrombolytic enzyme molecules that specifically bind to thrombi and are linked to enzymatically active portions of thrombolytic enzymes, enhancing their therapeutic potential.

Career Highlights

Throughout his career, Marschall S Runge has been associated with esteemed institutions such as Emory University and The General Hospital Corporation. His work has significantly advanced the understanding and treatment of coagulation disorders, making him a key figure in the field.

Collaborations

Runge has collaborated with notable individuals in his field, including John S Lollar and Edgar Haber. These partnerships have contributed to the development of innovative solutions in medical research and therapy.

Conclusion

Marschall S Runge's contributions to the field of biotechnology, particularly in the development of hybrid factor VIII and thrombolytic enzyme molecules, highlight his role as a leading inventor. His work continues to impact the medical community and improve patient outcomes.